US Patent Issued to THE KITASATO INSTITUTE, LIPOPROTEIN RESEARCH STOCKHOLM on April 21 for "Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor and pharmaceutical use therefor" (Swedish, Japanese Inventors)

ALEXANDRIA, Va., April 21 -- United States Patent no. 12,605,359, issued on April 21, was assigned to THE KITASATO INSTITUTE (Tokyo) and LIPOPROTEIN RESEARCH STOCKHOLM AB (Stockholm).

"Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor and pharmaceutical use therefor" was invented by Hiroshi Tomoda (Sagamihara, Japan), Tohru Nagamitsu (Sagamihara, Japan), Satoshi Omura (Sagamihara, Japan), Paolo Parini (Stockholm), Osman Ahmed (Stockholm), Matteo Pedrelli (Stockholm), Camilla Pramfalk (Stockholm) and Mats Eriksson (Stockholm).

According to the abstract* released by the U.S. Patent & Trademark Office: "A low-molecular weight compound having an activity of inhibiting the functions of proprotein convertase subtilisin/kexin type ...